Refine Results
  1. "Lancet Oncology"
Formats
  1. Journal Article (276)
  2. Correspondence (14)
  3. Editorial (11)
  4. Guidelines (7)
  5. Review (7)
  6. Research Letter (1)
Groups
  1. Department of Medicine (189)
  2. Solid Tumor Oncology Division (157)
  3. Surgery (51)
  4. Genitourinary Oncology Service (41)
  5. Population Sciences Research Program (39)
  6. Hematologic Malignancies, Division of (36)

More Groups

People
  1. Robert Motzer (15)
  2. Howard Scher (13)
  3. Gregory Riely (11)
  4. Jedd Wolchok (11)
  5. David Ilson (10)
  6. Ghassan Abou-Alfa (9)

More People

Years
  1. 2022 (11)
  2. 2021 (33)
  3. 2020 (35)
  4. 2019 (25)
  5. 2018 (26)
  6. 2017 (30)

More Years

Publications
  1. Lancet Oncology (316)
Publishers
  1. Elsevier Science, Inc. (316)

Results (316)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): Final analysis of a randomised, open-label, phase 3 study
    Journal Article

    Diaz, L. A. Jr; Shiu, K. K.; Kim, T. W.; Jensen, B. V.; Jensen, L. H.; Punt, C.; Smith, D.; Garcia-Carbonero, R.; Benavides, M.; Gibbs, P.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Patient-reported outcomes: What really matters to patients? – Authors' reply
    Correspondence

    Cella, D.; Choueiri, T.K.; Motzer, R. J.
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Cancer research collaboration between the UK and the USA: Reflections on the 2021 G20 Summit announcement
    Editorial

    Sullivan, R.; Lewison, G.; Torode, J.; Kingham, P. T.; Brennan, M.; Shulman, L. N.; Lawler, M.; Aggarwal, A.; Gralow, J.
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • ARCS-M: Forging progress from this negative trial in malignant pleural mesothelioma
    Editorial

    Zauderer, M. G.; Offin, M.
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Climate crisis and cancer: Perspectives from the hardest hit
    Correspondence

    Eala, M. A. B.; Robredo, J. P. G.; Dee, E. C.; Lin, V.; Lagmay, A. M. F. A.
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Post-protocol therapy and informative censoring in the CANDOR study – Authors' reply
    Correspondence

    Usmani, S. Z.; Li, C.; Obreja, M.; Dimopoulos, M.
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: An open-label, randomised, phase 3 trial
    Journal Article

    Cella, D.; Motzer, R. J.; Suarez, C.; Blum, S. I.; Ejzykowicz, F.; Hamilton, M.; Wallace, J. F.; Simsek, B.; Zhang, J.; Ivanescu, C.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): A multicentre, randomised, phase 3 trial
    Journal Article

    Safran, H. P.; Winter, K.; Ilson, D. H.; Wigle, D; DiPetrillo, T; Haddock, M .; Hong, T. S.; Leichman, L. P.; Rajdev, L.; Resnick, M.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Radiographic progression-free survival in the ACIS trial for prostate cancer - Authors' reply
    Correspondence

    Saad, F.; De Porre, P.; Brookman-May, S.; Li, J.; McCarthy, S. A.; Rathkopf, D. E.
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Prioritising access to cancer drugs
    Correspondence

    Puyat, C. V. M.; Eala, M. A. B.; Dee, E. C.; Tantengco, O. A. G.; Cruz, A. R. D. P.; Faylona, E. A.; Germar, M. J. V.; Sacdalan, D. L.
    Lancet Oncology (2022)

    Fulltext@MSK | Save